Andy Cunningham Joins Olatec Therapeutics Board of Directors

NEW YORK, Oct. 2, 2025 /PRNewswire/ -- Olatec Therapeutics, Inc., a leader in the emerging class of specific NLRP3 inhibitors, today announced that Andy Cunningham had joined its Board of Directors. She succeeds Valentín Campos, who retired from the Board after 9 years of service.

Ms. Cunningham brings four decades of proven expertise in strategic communication, marketing and branding across diverse sectors ranging from technology to healthcare. Throughout her distinguished career, she has played a key role in launching several categories and businesses within the technology and healthcare industries. Her career in Silicon Valley began at Regis McKenna, Inc. in 1983 working with Steve Jobs on the launch of Apple's Macintosh. This led her to start a public relations firm, Cunningham Communications, Inc. There she worked closely with Jobs on launching his new company NeXT as well as the acquisition of Pixar. Since then, Ms. Cunningham has developed branding and communication strategies for many of the world's most influential companies, including Adobe, Cisco, Facebook, Google, Oracle, Snowflake, Xerox. In addition to serving on various corporate boards, including The Trade Desk, she is a trustee of Aspen Institute and The Computer History Museum. She is also an advisor to several startups in the AI and healthcare markets. Ms. Cunningham has taught marketing at leading universities including Stanford, Harvard, Carnegie Mellon and Northwestern.

"Olatec has made significant strides in positioning dapansutrile at the forefront of the emerging NLRP3 inhibitor class. Over the past year, Andy has worked closely with us to build a marketing foundation to amplify this mission and enhance our visibility among key stakeholders. As Andy joins our Board, I am confident her expertise in strategic communication and stakeholder engagement will enhance the Company's position as we advance into the next critical stage of development. I also extend my deep gratitude to Valentín for his contributions and dedicated service to Olatec over the years," said Damaris Skouras, Chairman and Chief Executive Officer of Olatec.

"I am honored to join Olatec's Board of Directors at this pivotal stage in the Company's growth," said Ms. Cunningham. "Olatec's mission to translate groundbreaking science into potentially transformative therapeutics that combat the detrimental effects of chronic inflammation could have an important impact on human health. I am excited and motivated to join the Board and do my part in assisting the Company to realize its goals."

About Olatec Therapeutics, Inc.
Olatec is a clinical stage biotech company at the forefront of an emerging class of innovative, oral inflammation therapeutics. The Company's lead drug candidate, dapansutrile, is a proprietary specific NLRP3 inhibitor. We have advanced dapansutrile from discovery to its current later-stage clinical development in arthritis, diabetes, neuroinflammatory diseases and cancer. Dapansutrile is positioned to become a breakthrough treatment with early human data showing its potential to safely modulate the body's immune system allowing for the restoration of immune balance, a necessary step to treat or prevent disease progression and prognosis in patients. Our preclinical and clinical studies have been published in top medical and scientific journals such as The Lancet, Proceedings of National Academy of Sciences,Journal of Cardiovascular Pharmacology. On the strength of dapansutrile's benign safety profile and robust clinical data, our clinical trials are now being conducted in well-known international centers of excellence such as Duke Cancer Institute in collaboration with Merck, the rheumatology department at NYU Langone, the neurosciences clinic at the University of Cambridge, and the immuno-endocrinology department at the University of Basel. Our mission is to translate scientific potential into medical practice and become best-in-class in treating chronic inflammation that drives disease progression with a cost-effective and patient-friendly (orally dosed) therapeutic.

Disclaimer & Forward-looking Statement
This press release is not an offer to sell and is not soliciting an offer to buy any equity interests in Olatec. The information contained herein is being provided for information purposes only. Olatec makes no express or implied representation or warranty as to the completeness of this information. Any forward-looking statements contained in this release are based on assumptions made by Olatec at the time this Press Release was prepared. Any forward-looking statement contained in this Press Release is subject to known and unknown risks, uncertainties and other factors that may be materially different from those contemplated in such forward-looking statements. All information with respect to industry data has been obtained from sources believed to be reliable and current, but the accuracy thereof cannot be guaranteed. Olatec does not undertake any obligation to update or revise the forward-looking statements contained in this Press Release to reflect events or circumstances occurring after the date this Press Release was prepared, or to reflect the occurrence of unanticipated events.

SOURCE Olatec Therapeutics, Inc.